Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays

Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor

(2010) Jean-Luc Martinoli et al.   THROMBOSIS AND HAEMOSTASIS

Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects

(2009) Xia Zhao et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery

(2009) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study

(2008) H. R. Buller et al.   BLOOD

Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development

(2008) Bengt I Eriksson et al.   CLINICAL PHARMACOKINETICS

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

(2008) Dagmar Kubitza et al.   CURRENT MEDICAL RESEARCH AND OPINION

Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): Relation to FXa-activity and influence of assay modifications

(2008) Sebastian Harder et al.   THROMBOSIS RESEARCH